Accredo Health Group, Inc.

Accredo Health Group, Inc., a for-profit pharmacy benefit management company based in Memphis, Tennessee, and a subsidiary of Express Scripts, specializes in distributing complex, high-value specialty pharmaceutical products to federal agencies, particularly the Department of Veterans Affairs. The company has maintained active federal contracting relationships since its SAM.gov registration on February 19, 2007, and holds a current registration valid through February 26, 2026. Accredo operates as a prime contractor providing critical medication distribution services across the VA's nationwide network of Veterans Integrated Service Networks (VISNs), delivering time-sensitive, specialized pharmaceutical treatments to support the healthcare needs of veterans.

Accredo Health Group has generated substantial federal contract volume through numerous firm fixed-price purchase orders issued exclusively by the Department of Veterans Affairs across multiple VISNs, including VISN 1, 2, 4, 5, 6, 9, 12, 16, 20, 21, 22, and 23, with contract values ranging from approximately $1,485 to $184,877 per award. The company supplies a diverse portfolio of specialty medications addressing complex medical conditions, including pulmonary arterial hypertension treatments such as Tyvaso (treprostinil), Uptravi (selexipag), Opsumit (macitentan), and Prolastin; neuropathic lysosomal storage disorder treatments including Lumryz (sodium oxybate); Parkinson's disease medications such as Duopa; ophthalmic conditions treatments including Oxervate (cenegermin) and Oxiviate; and other specialized pharmaceuticals such as Palynziq, Hetlioz (tasimelteon), Filspari, and Tyvasco. Contract awards typically include both routine supply orders and emergency pharmaceutical procurements, with ultimate completion dates generally ranging from one to several months following award. All identified federal contracts are structured as purchase orders without set-aside designations, indicating that Accredo competes on an unrestricted basis for these opportunities. Additionally, Accredo has received a single small contract from the Metropolitan Detention Center Los Angeles for specialty medication delivery valued at $1,485, demonstrating limited diversification beyond VA contracts.